# LaNova Medicines

Source: https://onco.cc/companies/lanova-medicines/  
OnCo record `lanova-medicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LaNova Medicines is a China-based biotechnology company running 10 late-stage cancer trials of LM-168, LM-108 and LM-299 in gastric & gastro-oesophageal junction cancer.

## Summary

LaNova Medicines, based in Shanghai, China, is a biotechnology company. LaNova Medicines is a clinical-stage biopharmaceutical company developing monoclonal antibodies, antibody-drug conjugates and bispecific antibodies for tumour immunology and the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 10 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing LM-168, LM-108, LM-299, LM101 and LM-350 in gastric & gastro-oesophageal junction cancer. The largest, NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), plans to enrol 400 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: LaNova Medicines Limited
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.lanovamedicines.com

## Sources

- Official website: https://www.lanovamedicines.com
- ClinicalTrials.gov: trials led by LaNova Medicines: https://clinicaltrials.gov/search?lead=LaNova%20Medicines%20Limited
- Pipeline page: https://www.lanovamedicines.com/en

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [LM-108](https://onco.cc/drugs/lm-108/)
- trials: [A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study](https://onco.cc/trials/nct05934331/), [A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors](https://onco.cc/trials/nct05615974/), [A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours](https://onco.cc/trials/nct06682780/), [A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct05518045/), [A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours](https://onco.cc/trials/nct06868199/), [A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct07669415/), [A Study of LM-24C5 For Advanced Solid Tumors](https://onco.cc/trials/nct06187402/), [A Study of LM-350 in Subjects With Advanced Solid Tumours](https://onco.cc/trials/nct07112222/), [LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma](https://onco.cc/trials/nct07362186/), [Phase II Study of LM-24C5](https://onco.cc/trials/nct07387081/), [Study of LM-299 in Subjects Advanced Malignant Tumors](https://onco.cc/trials/nct06650566/)

---
JSON: https://onco.cc/api/v1/entities/lanova-medicines.json